Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

ent options for physicians and their patients." 

About Lung Cancer

Lung cancer is the second most common cancer and kills more people than any other cancer.  In 2010, approximately 222,250 new cases of lung cancer will be diagnosed in the United States, with 157,300 Americans dying from the disease.   NSCLC is the most common form of lung cancer, accounting for about 85% of all lung cancers.(4)  Lung cancer remains an area of high unmet need, especially in its advanced stages where it is particularly aggressive and patients have limited treatment options. There is no FDA-approved therapy for patients with advanced lung cancer who have failed chemotherapy and progressed after treatment with an EGFR TKI.

About Afatinib's Clinical Trial Program: LUX Trial Program

The LUX trial program is a comprehensive and robust program that comprises more than 10 trials conducted across the globe, investigating afatinib in a variety of different solid tumor types, including NSCLC, breast and head and neck cancer.

LUX-Lung 1 is a phase IIb/III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and first-generation EGFR TKIs, erlotinib or gefitinib.

LUX-Lung 2 is a phase II trial evaluating afatinib in NSCLC patients with EGFR mutations, either treatment naïve or after one line of chemotherapy.

In two ongoing global phase III trials, LUX-Lung 3 and LUX-Lung 6, the efficacy and safety of afatinib is compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations in different geographical regions.

Another trial, LUX-Lung 5, is a global phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015 ... DESI are increasing in applications as their ... research firm Kalorama Information.  Kalorama Information says ... MS) is the most powerful tool in ... (mass spec; MS) through its traditional techniques ...
(Date:2/26/2015)... 2015  AbbVie (NYSE: ABBV ) ... its neuroscience and oncology development programs have been ... American Academy of Neurology annual meeting in ... The accepted abstracts feature results from studies evaluating ... treatments in AbbVie,s pipeline. Presentations will include Phase ...
(Date:2/26/2015)...  Mail-service and specialty pharmacies will save ... health plans $23.3 billion over the next decade, ... Management Association (PCMA). "Home delivery of ... easiest ways to reduce health costs," said PCMA ... should resist efforts to restrict these cost-saving tools." ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2
... PROMUS(TM) Element(TM) Platinum Chromium StentNATICK, Mass., Feb. 3 ... announced the beginning of patient enrollment in the PLATINUM ... PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent. The first U.S. ... of the Rockies in Loveland, Colorado by Thomas Downes, ...
... Adolescents and young adults who are heavy users ... have disrupted brain development, according to a new ... the brain that interconnect brain regions involved in ... The findings are of particular concern because adolescence ...
Cached Medicine Technology:Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 2Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 3Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 4Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 5Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults 2Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults 3
(Date:2/28/2015)... FL (PRWEB) February 28, 2015 The ... training and learning materials to potential EMTs and firefighters, ... for Bitcoins as a way to raise charitable donations ... ends in Medellin, Columbia, will be held on March ... the run will begin at 3:30 p.m. , ...
(Date:2/27/2015)... Calif. (PRWEB) February 27, 2015 Hispanics ... liver-disease death, between four and 12 years earlier than ... from UC Davis Health System. , While previous research ... than other populations, the new study -- published online ... is believed to be the first to pinpoint racial ...
(Date:2/27/2015)... A new study published in the Journal of ... on a regular basis and prostate cancer. While cycling is ... more hours per week a man spends cycling, the more ... increased importance on prostate cancer screening methods. , “This study ... at patents’ risk factors for developing prostate cancer,” says Kia ...
(Date:2/27/2015)... 27, 2015 Today, February 27th, is "Shine ... , along with LXR Organics and Living ... Campaign to raise awareness and promote prevention, rescue and restoration ... by the END IT Coalition, slavery is the 2nd largest ... exists in 167 countries around the world. Slavery includes bonded ...
(Date:2/27/2015)... Altec Products, Inc., announced today that Bartlett, ... their doc-link for Dynamics Partner of the Year. BPW ... for their customers in all different industries with a ... BPW have worked side-by-side to successfully help clients implement ... “We are so impressed by the success that BPW ...
Breaking Medicine News(10 mins):Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... Obesity Rates Rise - Webinar to Crack the Code, ... insights from a,comprehensive study of over 1,000 U.S. adults ... as diet and exercise guidelines. In,"Wellness in America: Lifestyles ... to achieve personal health and wellness goals is,explored and ...
... evidence that noncoding RNAs and interactions between noncoding genes ... was previously understood. The research, published by Cell Press ... may be useful for identifying tumor-specific signatures associated with ... exhibit genetic alterations in oncogenes or tumor suppressor genes. ...
... Nearly 30 years after Nobel laureate Linus Pauling famously and ... team of Johns Hopkins scientists have shown that in mice ... can indeed inhibit the growth of some tumors just ... , The conventional wisdom of how antioxidants such as vitamin ...
... Sept. 10, 2007 Smoking, eating fattening foods and ... lead to poor health and cardiovascular disease more so ... Southwestern Medical Center have found that women dont change these ... with heart disease. , The scientists, reporting in the September ...
... See" Approach to Identifying,Learning Disabilities, SAN MATEO, ... of the Charles and Helen Schwab Foundation dedicated ... problems,announced today their launch of a new interactive ... a learning problem. This one-of-a-kind,resource, "When Your Child ...
... Sept. 10 Genomic,Health, Inc. (Nasdaq: GHDX ... the use of quantitative real-time polymerase chain reaction,(RT-PCR), ... measuring the hormone,receptors, estrogen receptor (ER) and progesterone ... study identified multiple genes,including the 21 genes in ...
Cached Medicine News:Health News:Why Are Most Health & Wellness Products Doomed to Failure? 2Health News:Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas 2Health News:How vitamin C stops the big 'C' 2Health News:Women less likely than men to change habits that increase heart disease risk 2Health News:Schwablearning.Org Launches Interactive Tool to Help Parents of Children Struggling in School 2Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 2Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 3Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 4
Immuno-turbidimetric Assay of von Willebrand Factor (vWF) Antigen by STA© Analyzers. Microlatex particles coated with rabbit anti-human vWF antibodies....
Substrate Plasma for Factor XII Assay by STA© Analyzers. Freeze-dried human plasma lacking factor XII....
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests....
Enzyme Immunoassay of Tissue Plasminogen Activator Antigen by ELISA Method, 96 tests....
Medicine Products: